NEWSROOM
News & Stories
Newsroom
Press Releases
MammaPrint & 3-year outcome of CT with/without anthracycline-ASCO 2024
Association of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline
Read MoreAgendia to Unveil Robust Suite of Data at 2024 ASCO
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read MoreGerman Gynecological Oncology Group (AGO) includes BluePrint® in Guidelines
German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines
Read More